Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service colonoscopy & upper endoscopy cases in Minnesota: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 1% on average (255 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 409 | 57,526 | 49% |
| 2020 | 375 | 43,907 | 52% |
| 2021 |
Diagnostic and therapeutic colonoscopy and EGD; identifies every active endoscopist. Professional codes (what the surgeon bills): CPT 45378, 45380, 45385, 45390, 43239, 43235, 43251.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 9% of the cases CMS names in Minnesota; 202 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| ERCP & endoscopic ultrasound | 37 | 2,446−5.1%/yr | −5.1%/yr | 5.51.4× | 3% | 3,110 in 2030+4.1%/yr |
| Bronchoscopy & lung nodule |
Colonoscopy & upper endoscopy in every state, and its device makers · Every procedure market in Minnesota · Every state · Compare with Illinois
| 2024 |
| 47,636 |
| 64% |
| 2025 est. | ≈ 47,800 | – |
| 2026 est. | ≈ 53,800 | – |
| 398 |
| 52,471 |
| 56% |
| 2022 | 400 | 47,861 | 59% |
| 2023 | 396 | 48,990 | 62% |
| 2024 | 399 | 47,636 | 64% |
| 2025 from claims | – | 47,821 43,887–50,595 | 65% |
| 2026 forecast | – | 53,764 47,304–62,042 | 61% |
| 2027 forecast | – | 55,131 47,131–65,699 | 61% |
| 2028 forecast | – | 56,530 47,169–69,220 | 61% |
| 2029 forecast | – | 57,964 47,343–72,692 | 60% |
| 2030 forecast | – | 59,432 47,613–76,162 | 60% |
In 2025, 9% inpatient hospital, 56% hospital outpatient, 33% surgery center, 2% office. The share outside the hospital has moved +8 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient | Surgery center | Office |
|---|---|---|---|---|
| 2026 · ~53,800 | ~4,800 | ~29,900 | ~18,000 | ~1,100 |
| 2027 · ~55,100 | ~4,900 | ~30,500 | ~18,600 | ~1,100 |
| 2028 · ~56,500 | ~5,000 | ~31,200 | ~19,200 | ~1,100 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: surgery center about 34% (33% in 2025), hospital outpatient about 55% (56% in 2025). More of these cases each year are decided in surgery centers, where the surgeons often own the center and weigh price and turnaround.
| 134,256−3.1%/yr |
| −3.1%/yr |
| 126.7 |
| 38% |
| 138,100 in 2030+0.5%/yr |
| Michigan | 560 | 87,395−7.5%/yr | −7.5%/yr | 108.4 | 36% | 82,100 in 2030−1%/yr |
| Indiana | 415 | 79,616−4.3%/yr | −4.3%/yr | 117.3 | 30% | 80,600 in 2030+0.2%/yr |
| Missouri | 371 | 72,989−5%/yr | −5%/yr | 122.5 | 27% | 74,000 in 2030+0.2%/yr |
| Wisconsin | 332 | 60,336−2.2%/yr | −2.2%/yr | 111.6 | 20% | 63,900 in 2030+1%/yr |
| Kansas | 167 | 36,685−2%/yr | −2%/yr | 93.1 | 28% | 39,000 in 2030+1%/yr |
| Iowa | 161 | 33,135−2.3%/yr | −2.3%/yr | 76.7 | 39% | 35,000 in 2030+0.9%/yr |
| Nebraska | 135 | 27,462−1.7%/yr | −1.7%/yr | 108.2 | 51% | 28,600 in 2030+0.7%/yr |
| South Dakota | 70 | 15,668−1.4%/yr | −1.4%/yr | 124.2 | 20% | 16,700 in 2030+1%/yr |
| North Dakota | 47 | 10,191−0.7%/yr | −0.7%/yr | 105.1 | 16% | 11,000 in 2030+1.3%/yr |
| 28 |
| 1,774+6.4%/yr |
| +6.4%/yr |
| 4.01.1× |
| 0% |
| 3,640 in 2030+13%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Boston Scientific leads with 37% of company spending on these surgeons in 2025, −30 pts on 2024.
In 2025, 17 companies reported engagement with Minnesota’s surgeons worth $76K in consulting, speaking, meals and travel tied to these products, about $191 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 13 clearances and approvals in the category.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.